A novel integrated gene coexpression analysis approach reveals a prognostic three-transcription-factor signature for glioma molecular subtypes

BackgroundGlioma is the most common brain tumor and it has very high mortality rate due to its infiltration and heterogeneity. Precise classification of glioma subtype is essential for proper therapeutic treatment and better clinical prognosis. However, the molecular mechanism of glioma is far from clear and the classical classification methods based on traditional morphologic and histopathologic knowledge are subjective and inconsistent. Recently, classification methods based on molecular characteristics are developed with rapid progress of high throughput technology.MethodsIn the present study, we designed a novel integrated gene coexpression analysis approach, which involves differential coexpression and differential regulation analysis (DCEA and DRA), to investigate glioma prognostic biomarkers and molecular subtypes based on six glioma transcriptome data sets.ResultsWe revealed a novel three-transcription-factor signature including AHR, NFIL3 and ZNF423 for glioma molecular subtypes. This three-TF signature clusters glioma patients into three major subtypes (ZG, NG and IG subtypes) which are significantly different in patient survival as well as transcriptomic patterns. Notably, ZG subtype is featured with higher expression of ZNF423 and has better prognosis with younger age at diagnosis. NG subtype is associated with higher expression of NFIL3 and AHR, and has worse prognosis with elder age at diagnosis. According to our inferred differential networking information and previously reported signalling knowledge, we suggested testable hypotheses on the roles of AHR and NFIL3 in glioma carcinogenesis.ConclusionsWith so far the least biomarkers, our approach not only provides a novel glioma prognostic molecular classification scheme, but also helps to explore its dysregulation mechanisms. Our work is extendable to prognosis-related classification and signature identification in other cancer researches.

[1]  Nada Jabado,et al.  Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups , 2014, Clinical Cancer Research.

[2]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[3]  A. G. de la Fuente.  From 'differential expression' to 'differential networking' - identification of dysfunctional regulatory networks in diseases. , 2010, Trends in genetics : TIG.

[4]  Hui Yu,et al.  Link-based quantitative methods to identify differentially coexpressed genes and gene Pairs , 2011, BMC Bioinformatics.

[5]  S. Partap,et al.  Update on new treatments and developments in childhood brain tumors , 2007, Current opinion in pediatrics.

[6]  M. Weller,et al.  Aryl hydrocarbon receptor inhibition downregulates the TGF-β/Smad pathway in human glioblastoma cells , 2009, Oncogene.

[7]  N. Seki,et al.  The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer , 2011, British Journal of Cancer.

[8]  Yair Lotan,et al.  Decreased DOC-2/DAB2 Expression in Urothelial Carcinoma of the Bladder , 2007, Clinical Cancer Research.

[9]  Charlotte Soneson,et al.  A glioma classification scheme based on coexpression modules of EGFR and PDGFRA , 2014, Proceedings of the National Academy of Sciences.

[10]  Lei Liu,et al.  Combinatorial network of primary and secondary microRNA-driven regulatory mechanisms , 2009, Nucleic acids research.

[11]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[12]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[13]  Olivier Delattre,et al.  Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth. , 2012, Cancer research.

[14]  L. Opanashuk,et al.  The Aryl Hydrocarbon Receptor Contributes to the Proliferation of Human Medulloblastoma Cells , 2012, Molecular Pharmacology.

[15]  K. Strebhardt,et al.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.

[16]  M. Weller,et al.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor , 2011, Nature.

[17]  Wei Yan,et al.  Prognostic Value of a Nine‐Gene Signature in Glioma Patients Based on mRNA Expression Profiling , 2014, CNS neuroscience & therapeutics.

[18]  A. Baldini,et al.  DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer , 1998, Oncogene.

[19]  Amy P N Skubitz,et al.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers. , 2004, The American journal of pathology.

[20]  A Kramar,et al.  [Estimate of adjusted survival curves]. , 1990, Revue d'epidemiologie et de sante publique.

[21]  Benjamin Haibe-Kains,et al.  A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? , 2008, Bioinform..

[22]  Pablo Tamayo,et al.  Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Jan Koster,et al.  NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome , 2010, Cell.

[24]  Aedín C. Culhane,et al.  survcomp: an R/Bioconductor package for performance assessment and comparison of survival models , 2011, Bioinform..

[25]  Jan Koster,et al.  ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. , 2009, Cancer cell.

[26]  Subha Madhavan,et al.  Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research , 2009, Molecular Cancer Research.

[27]  K. Aldape,et al.  The Use of Global Profiling in Biomarker Development for Gliomas , 2011, Brain pathology.

[28]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[29]  Lei Han,et al.  Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. , 2012, Neuro-oncology.

[30]  Martin Sill,et al.  Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma , 2014, Acta Neuropathologica.

[31]  Akira Yamaura,et al.  Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis , 2004, Cancer Research.

[32]  Kaiming Gao,et al.  Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma , 2014, Journal of experimental & clinical cancer research : CR.

[33]  Feng Q. He,et al.  Reverse engineering and verification of gene networks: principles, assumptions, and limitations of present methods and future perspectives. , 2009, Journal of biotechnology.

[34]  Swati Sinha,et al.  Identification of Genomic Targets of Transcription Factor Aebp1 and its role in Survival of Glioma Cells , 2012, Molecular Cancer Research.

[35]  Yu-Bo Xie,et al.  Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance , 2014, BMC Cancer.

[36]  Jiri Petrak,et al.  Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics. , 2011, Oncology reports.

[37]  Hui Yu,et al.  Combinatorial network of transcriptional regulation and microRNA regulation in human cancer , 2012, BMC Systems Biology.

[38]  D. DeMeo,et al.  Molecular biomarkers for quantitative and discrete COPD phenotypes. , 2009, American journal of respiratory cell and molecular biology.

[39]  Pablo R. Freire,et al.  Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. , 2013, Neuro-oncology.

[40]  Zhongming Zhao,et al.  DCGL v2.0: An R Package for Unveiling Differential Regulation from Differential Co-expression , 2013, PloS one.

[41]  Jeffrey Field,et al.  Pak protein kinases and their role in cancer , 2009, Cancer and Metastasis Reviews.

[42]  Toshihiko Wakabayashi,et al.  Immunohistochemical analysis‐based proteomic subclassification of newly diagnosed glioblastomas , 2012, Cancer science.

[43]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[44]  Andrea Califano,et al.  Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. , 2013, Genes & development.

[45]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[46]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[47]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[48]  Bob S Carter,et al.  RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls , 2012, BMC Cancer.

[49]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[50]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[51]  Hui Yu,et al.  Bioinformatics Applications Note Gene Expression Dcgl: an R Package for Identifying Differentially Coexpressed Genes and Links from Gene Expression Microarray Data , 2022 .